Recursion Pharmaceuticals Inc. (RXRX) — RQD Stock Rating Cockpit
Recursion Pharmaceuticals Inc. (RXRX) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
Weak cash conversion or heavy valuation strain compared to actual cash earned.
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
2-of-3 JEV AI Jury Bearish Warning on RXRX
-35.0% ROIC with 5.0% gross margin and -14.95% FCF yield.
Flagged cash-conversion divergence or elevated filing risk disclosures.
Put/Call 0.99x with 22/40 institutional & insider flow.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring RXRX)
- ✓Live walkthrough of RXRX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RXRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +26.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RXRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RXRX. Explore sector supply chains on /butterfly.
RXRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell RXRX stock right now?
Recursion Pharmaceuticals Inc. (RXRX) currently earns a Roarable Rating of D+ (Sell — SELL) with 58/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
What is RXRX's 12-month price target and RQD AI Jury consensus?
RXRX's 12-month base price target is $4.24 (range $3.31 to $6.05), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.